Galectin Therapeutics (GALT) 10-Q2014 Q1 Quarterly report

Content analysis

Filed: 13 May 14, 12:00am

Date: May 13, 2014

/s/ Jack W. Callicutt

Jack W. Callicutt

Chief Financial Officer

(principal financial and accounting officer)

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: Acorn, afford, architecture, area, attached, billion, breast, built, burgeoning, cellular, checkpoint, collagen, competent, confluent, costly, crystal, damage, distribution, Donabedian, drugability, dysfunction, EACRI, Earle, effort, encouraging, enforce, exemption, expand, fight, flexibility, foreign, formation, hit, improve, inhibitor, Investee, joint, largely, led, LLC, molecule, optimized, oral, organ, organic, pending, point, portion, proceeding, proportionate, prostate, recent, registration, relied, repair, replace, representing, sarcoma, SBH, scarring, screened, shelf, shrinkage, silico, small, source, sponsorship, stimulatory, Superior, supplement, survival, synthesized, synthetic, thereunder, tissue, type, venture

Removed: advancement, agreed, appointed, approved, asset, assignment, assist, assisting, authorization, Belgian, Belgium, biotechnology, breach, budget, building, calculated, cell, Centre, classified, collaboration, collectively, collocated, colorectal, commitment, contractual, converted, CR, cured, de, deadly, decreased, DEFICIT, deposit, developed, developing, disposing, dissolved, enrolled, entitle, essential, Europe, evasion, explored, extended, factor, FAMHP, Federal, flow, funded, funding, GA, gene, halted, hepatic, highly, holder, IMPD, improbable, incapable, indemnification, inflammatory, informing, initiated, initiative, injected, insolvent, inspecting, insult, intravenously, invasion, invested, involvement, lab, lack, lacking, lease, liability, line, liquidated, longer, Ludwig, Luxembourg, main, Master, Medicine, merit, modified, monthly, ninety, nonalcoholic, offset, open, originally, partial, performed, positive, PR, preliminary, principal, progressed, progression, promoting, Published, realized, receiver, RECIST, redeemable, relocation, rent, rental, resistant, responsible, Restated, reviewing, scaring, security, selecting, september, skin, sooner, space, sponsor, sponsored, startup, strongly, substantial, substantially, Super, supply, term, terminate, terminated, thirty, top, toxin, undertaken, unused, vaccine, written

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

GALT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Galectin Therapeutics Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jack W. Callicutt, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Galectin Therapeutics Inc. and will be retained by Galectin Therapeutics Inc. and furnished to the Securities and Exchange Commission or its staff upon request.